Clocinnamox

Clocinnamox
Clinical data
Other names	C-CAM; CCAM; NIH-10443
Identifiers
	IUPAC name (E)-N-[(4R,4aS,7aR,12bR)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl]-3-(4-chlorophenyl)prop-2-enamide; or; (2E)-3-(4-chlorophenyl)-N-[(5α)-17-(cyclopropylmethyl)-3-hydroxy-6-oxo-4,5-epoxymorphinan-14-yl]acrylamide;
CAS Number	117332-69-1;
PubChem CID	6540640;
ChemSpider	5022878;
ChEMBL	ChEMBL386492;
Chemical and physical data
Formula	C29H29ClN2O4
Molar mass	505.01 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)NC(=O)/C=C/C7=CC=C(C=C7)Cl;
	InChI InChI=1S/C29H29ClN2O4/c30-20-7-3-17(4-8-20)5-10-24(35)31-29-12-11-22(34)27-28(29)13-14-32(16-18-1-2-18)23(29)15-19-6-9-21(33)26(36-27)25(19)28/h3-10,18,23,27,33H,1-2,11-16H2,(H,31,35)/b10-5+/t23-,27+,28+,29-/m1/s1; Key:RAURUSFBVQLAPW-DNIKMYEQSA-N;

Clocinnamox (CCAM or C-CAM; developmental code name NIH-10443) is a selective and irreversible antagonist of the μ-opioid receptor. Closely related compounds include methocinnamox (MCAM) and methoclocinnamox (MCCAM). They were derived via structural modification of buprenorphine. Clocinnamox was first described in the scientific literature by 1992.